Oncology-New York最新文献

Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship. 为癌症幸存者开设多学科生活方式医学诊所。

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-11-05 DOI: 10.46883/2024.25921030

Rachel A Millstein, Loren Winters, Carol Sullivan, Stephanie Eisenstat, Emily Sorg, Amy Comander

{"title":"Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship.","authors":"Rachel A Millstein, Loren Winters, Carol Sullivan, Stephanie Eisenstat, Emily Sorg, Amy Comander","doi":"10.46883/2024.25921030","DOIUrl":"10.46883/2024.25921030","url":null,"abstract":"Background: Lifestyle medicine (LM) is increasingly recognized in cancer survivorship guidelines. The 6 LM pillars are physical activity, a predominantly plant diet, restorative sleep, stress management, avoiding risky substance use, and social connections. Through a multidisciplinary LM clinic in oncology, we describe 2 illustrative cases and the implications for broader implementation and dissemination of this clinic model.Methods: In the multidisciplinary LM clinic in oncology, patients meet with an American College of Lifestyle Medicine (ACLM) board-certified physician or nurse practitioner, a registered dietitian, and, as needed, a clinical psychologist, a psychiatrist, an obesity medicine physician, a physical therapist, and/or a rehabilitation medicine physician.Results: Patient 1 met with the physician, the registered dietitian, the psychologist, and an affiliated cancer center psychiatrist. Patient 2 met with the nurse practitioner and the registered dietitian. The 2 cases presented illustrate the diversity of LM pillars and strategies to increase health and well-being post cancer treatment.Conclusion: This paper details the model of implementation of a novel oncology-focused multidisciplinary LM clinic and the clinical focuses of 2 diverse patients. The LM needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of LM for this population can enhance the quality of life for patients who are survivors of cancer.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 11","pages":"421-425"},"PeriodicalIF":1.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment? 广撒网：177Lu-Dotatate 治疗的最佳时机是什么时候？

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-11-05 DOI: 10.46883/2024.25921029

Natasha Bahri, Christiana Crook, Daneng Li Md

引用次数: 0

The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion. 隐藏的危险揭开多发性骨髓瘤与胸腔积液之间的联系

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-11-05 DOI: 10.46883/2024.25921028

Fnu Fatima, Faryal Arif, Muhammad Hamza Gul, Neha Siddiqui, Muhammad Zulqarnain, Abdul Baseer Wardak

引用次数: 0

Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors. 遗传性肾肿瘤综合征与 mTOR 抑制剂的使用。

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-10-17 DOI: 10.46883/2024.25921027

José Luis Rodríguez-Olivares, Héctor Raúl González-Sánchez, Evelyn Lilian Beas-Lozano, Jazmin Arteaga-Vázquez, Elaine T Lam Md, María T Bourlon

{"title":"Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors.","authors":"José Luis Rodríguez-Olivares, Héctor Raúl González-Sánchez, Evelyn Lilian Beas-Lozano, Jazmin Arteaga-Vázquez, Elaine T Lam Md, María T Bourlon","doi":"10.46883/2024.25921027","DOIUrl":"10.46883/2024.25921027","url":null,"abstract":"The Case A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%. A chest CT scan revealed pulmonary cystic lesions consistent with lymphangioleiomyomatosis and a right spontaneous pneumothorax, which resolved with the placement of a chest tube. Physical examination revealed a hypopigmented macule on the skin of the lumbar region, facial angiofibromas, and periungual fibromas. An abdominal MRI documented multiple bilateral renal tumors that were hypointense on T2-weighted imaging and showed a black boundary artifact, suggestive of fat-poor angiomyolipomas (AMLs). Subsequent percutaneous biopsy of the largest renal tumor confirmed the diagnosis of angiomyolipoma (positive for HMB-45 on immunohistochemistry). The brain MRI revealed subependymal nodules. The pulmonary function tests showed a mild obstructive pattern. Germline genetic testing confirmed the suspected diagnosis, and the patient started oral systemic treatment with everolimus (Afinitor) 10 mg once daily, along with dexamethasone rinses for prophylaxis.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 10","pages":"376-380"},"PeriodicalIF":1.8,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care. 多学科团队会议：癌症护理中的实施障碍。

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-09-19 DOI: 10.46883/2024.25921026

Carl He

引用次数: 0

Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia. 范式转变的导航 Venetoclax 治疗重新定义了急性髓性白血病的前景。

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-08-19 DOI: 10.46883/2024.25921025

Muhammad Hamza Gul, Aisha Rehman Siddiqui, Farwa Zehra, Malaika Rehmani, Faraz Waheed, Natasha Masood, Maleeha Saqib, Mahnoor Keen, Sharan Siddharth Keshetty, Maham Maqsood, Siddharth Arjun Atwal, Muhammad Hamza Sikandari, Abdul Baseer Wardak

{"title":"Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia.","authors":"Muhammad Hamza Gul, Aisha Rehman Siddiqui, Farwa Zehra, Malaika Rehmani, Faraz Waheed, Natasha Masood, Maleeha Saqib, Mahnoor Keen, Sharan Siddharth Keshetty, Maham Maqsood, Siddharth Arjun Atwal, Muhammad Hamza Sikandari, Abdul Baseer Wardak","doi":"10.46883/2024.25921025","DOIUrl":"10.46883/2024.25921025","url":null,"abstract":"Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the accumulation of malignant myeloid progenitor hematopoietic cells in the bone marrow and peripheral blood. Recent studies have shown promising results with the use of small molecule inhibitors and targeted therapy in the treatment of patients with AML. One such molecule is venetoclax, which has been approved in AML by the FDA in combination with hypomethylating agents or low-dose cytarabine. We thoroughly searched electronic literature related to venetoclax and its role in AML, using databases such as MEDLINE, PubMed, Google Scholar, and PsychInfo, through April 2024. We applied population, intervention, comparison, and outcome criteria, specifically focusing on studies with a population using venetoclax from review articles and clinical trials. All selected studies were required to be in English, and any study that did not involve the use of venetoclax was excluded. A meticulous literature review was conducted to consolidate the current knowledge and new combination therapies on AML. In our review article, we focused on the latest advances in the treatment of patients with AML. Based on the literature, we recommend that physicians prioritize the use of venetoclax in the management of this deadly disease because it has been shown to significantly impact the course of the disease.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 8","pages":"311-314"},"PeriodicalIF":1.8,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs. 新辅助卡培他滨加替莫唑胺治疗非典型肺NET

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-07-08 DOI: 10.46883/2024.25921024

Georgios Evangelou, Ioannis Vamvakaris, Irene Konstantopoulou, Konstantinos Syrigos

{"title":"Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs.","authors":"Georgios Evangelou, Ioannis Vamvakaris, Irene Konstantopoulou, Konstantinos Syrigos","doi":"10.46883/2024.25921024","DOIUrl":"10.46883/2024.25921024","url":null,"abstract":"Neoadjuvant and adjuvant treatment in lung neuroendocrine tumors (NETs) is a field that has not been explored in-depth, with little information on the impact on disease-free survival. This case study highlights the effectiveness of neoadjuvant treatment with capecitabine plus temozolomide (CAPTEM) in a woman with well-differentiated atypical carcinoid. The patient was asymptomatic at diagnosis and was referred to the outpatient NET clinic at Sotiria Hospital in Athens, following an incidental finding on a chest x-ray. 18F-fluorodeoxyglucose (FDG) PET/CT and 68Ga-Dotatoc PET/CT revealed another mass in the pancreas, with avidity in both imaging studies. The patient underwent treatment for 6 months with CAPTEM with a response in the lung NET and mediastinal lymph nodes. However, the mass in the pancreas slightly increased and was removed with a central pancreatectomy. The patient continued treatment with CAPTEM for 6 more months. There was further response according to RECIST 1.1 criteria (partial response in the mediastinal lymph nodes and a 21% regression in the primary tumor size). Pathology report after lobectomy with lymph node dissection showed a pathologic complete response in the mediastinal lymph nodes. Twenty-four months after surgery, the patient remains disease-free and has a good quality of life. Although large clinical trials are needed, this case study underlines the value of preoperative chemotherapy in atypical carcinoids.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 7","pages":"264-268"},"PeriodicalIF":1.8,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation. 一例罕见的 CDKN2A 基因突变转移性螺旋状腺癌病例

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-06-10 DOI: 10.46883/2024.25921022

Jonathan Q Trinh, Shristi Upadhyay Banskota, Alissa S Marr

引用次数: 0

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials. 尽管试验结果呈阴性，Venetoclax 在 t(11;14) 多发性骨髓瘤中的应用依然成功。

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-06-10 DOI: 10.46883/2024.25921023

Zachary M Avigan, Joshua Richter Md

引用次数: 0

AI Use in Prostate Cancer: Potential Improvements in Treatments and Patient Care. 人工智能在前列腺癌中的应用：治疗和患者护理的潜在改进。

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-05-13 DOI: 10.46883/2024.25921021

James B Yu Md Mhs Fastro, Julian C Hong

引用次数: 0